Sotera Health (SHC) Q1 2026: Nordion Grows 26% as Segment Mix Drives Margin Expansion
Sotera Health’s Q1 2026 results highlight robust segment-driven growth and margin gains, despite mixed demand signals in testing services and regulatory overhangs. The company reaffirmed full-year guidance, with Sterigenics and Nordion delivering standout performances and margin expansion, while Nelson Labs remains in a transition phase. A CEO transition and regulatory developments set the stage for continued operational focus and potential market share shifts.
Summary
- Segment Outperformance: Nordion’s volume-led surge and Sterigenics’ resilient pricing offset Nelson Labs softness.
- Margin Expansion: Mix shift and pricing discipline drove consolidated margin gains, despite inflationary pressures.
- Leadership Transition: Incoming CEO inherits a stable platform, but faces regulatory and customer mix challenges.
Business Overview
Sotera Health is a global provider of mission-critical sterilization and lab testing services for the healthcare supply chain. The company operates through three main segments: Sterigenics, sterilization services for medical devices and pharma; Nordion, supplier of Cobalt-60 isotopes for gamma sterilization; and Nelson Labs, laboratory testing and expert advisory services. Revenue is anchored by long-term contracts with healthcare manufacturers, with over 70% of revenue recurring and supported by multi-year agreements.
Performance Analysis
Q1 2026 results revealed a healthy top-line expansion, with consolidated revenue up 6.5% in constant currency, and adjusted EBITDA rising 6.9%. Segment performance was uneven but strategically favorable: Sterigenics posted 6.1% constant currency growth, benefiting from 4.5% price realization and improved volume/mix, despite weather-related headwinds. Nordion delivered a standout quarter, growing constant currency revenue 25.8% on strong Cobalt-60 harvest timing and favorable mix, with segment margins expanding over 290 basis points. In contrast, Nelson Labs saw a 3.8% constant currency revenue decline, as volume and mix pressures outweighed modest price and currency benefits.
Margin expansion was a central theme, with overall adjusted EBITDA margins improving by over 20 basis points. This was achieved through disciplined pricing, operational leverage in Sterigenics, and a favorable shift in Nordion’s revenue mix. Cash generation remained positive, even after a $34 million legal settlement payment, and capital expenditures focused on Sterigenics expansions and regulatory upgrades. Net leverage improved to 3.2 times, approaching the long-term target range.
- Nordion Volume Spike: Cobalt-60 harvest timing and mix drove exceptional top-line and margin gains, but growth is expected to moderate in coming quarters.
- Sterigenics Pricing Power: Price increases above historical averages helped offset inflation and weather headwinds, with volume recovery in March and April supporting a constructive outlook.
- Nelson Labs Drag: Testing and advisory volumes continued to lag, but management expects margin recovery and a return to low single-digit growth in the second half.
Segment mix and pricing discipline are supporting margin resilience even as end-market demand remains variable. Investors should watch for normalization in Nordion and Nelson Labs execution as the year progresses.
Executive Commentary
"Our business model has demonstrated its resilience over time, delivering consistent revenue growth for the past two decades across multiple economic cycles. We sit in a unique position in the healthcare supply chain and take our mission of safeguarding global health very seriously."
Michael Petras, Chairman and Chief Executive Officer
"We saw margin improvement in the quarter. As the guide implies, we expect margin improvement in the year. That's really going to be driven from Sterigenics, where we expect to get some good operating leverage in the business and really stable margins on the other part of the segments."
John Lyons, Chief Financial Officer
Strategic Positioning
1. Sterigenics: Pricing Leverage and Capacity Readiness
Sterigenics, the core sterilization segment, continues to demonstrate pricing power, with 4.5% price increases driving growth above the long-term 3-4% target range. The business is targeting 80% utilization and is well-positioned on capacity, with new x-ray facility expansions scheduled and strong customer satisfaction scores reinforcing retention and share gains. Weather disruptions in Q1 were offset by a strong March and April, signaling robust demand recovery.
2. Nordion: Timing-Driven Growth, Margin Outperformance
Nordion’s Q1 surge was driven by Cobalt-60 harvest schedules, yielding a 25.8% revenue jump and over 290 basis points in margin expansion. This segment’s growth is inherently lumpy due to harvest timing, and management guides to low to mid-single digit growth for the full year. Pricing execution remains solid, but the outsized Q1 benefit is not expected to repeat in the second half.
3. Nelson Labs: Transition and Margin Recovery
Nelson Labs, the lab testing and advisory segment, remains the weakest link, with revenue down and margins pressured by volume/mix headwinds. Management expects the headwind from expert advisory services to abate after Q1, with routine testing volumes stabilizing and validation pipeline building. Full-year margins are forecasted to recover to the low to mid-30% range, but near-term growth will remain muted.
4. Regulatory and Legal Environment: Navigating Uncertainty
Recent legal wins in Georgia over ethylene oxide (EO) litigation reduce headline risk, but regulatory compliance remains a major capital and operational focus. Management is executing on $200 million of EO facility upgrades, and is preparing for evolving EPA rules that may further pressure smaller competitors and drive customer conversions to Sotera’s platform.
5. Leadership Transition: Stability and Continuity
The planned CEO transition to Alton Shader brings continuity and deep sector experience, while outgoing CEO Petras remains engaged as Executive Chair. The board refresh and growing public float (now ~90%) signal a maturing governance structure and potential for broader institutional ownership.
Key Considerations
Sotera Health’s Q1 2026 performance underscores the importance of segment mix, pricing discipline, and operational readiness in a regulated, contract-driven business model. Investors should weigh the following:
- Margin Drivers Remain Intact: Pricing and favorable mix continue to offset inflation and volume variability, especially in Sterigenics and Nordion.
- Regulatory Overhang Persists: Ongoing EO rulemaking and capital investment requirements may accelerate share gains from weaker competitors, but also constrain near-term cash flow.
- Nelson Labs Recovery Is Key: Return to growth and margin normalization in Nelson Labs is critical for sustaining consolidated margin expansion.
- Capital Allocation Focus: Free cash flow is prioritized for debt reduction and regulatory compliance, with no M&A assumed in guidance.
- Leadership Stability: Succession planning and board refresh support strategic continuity, but execution during transition will be closely watched.
Risks
Regulatory risk around ethylene oxide emissions remains elevated, with potential for increased compliance costs and shifting customer preferences if rules tighten. Segment growth in Nordion is inherently volatile due to Cobalt-60 harvest timing, and Nelson Labs’ recovery is not yet proven. Legal appeals and ongoing litigation could introduce further uncertainty, while inflation or wage pressure could erode margin if not offset by pricing.
Forward Outlook
For Q2 2026, Sotera Health guided to:
- Sterigenics revenue growth similar to Q1 on a constant currency basis
- Nelson Labs returning to slight growth, with margin improvement expected through the year
For full-year 2026, management reaffirmed guidance:
- Total company revenue of $1.233 billion to $1.251 billion (5% to 6.5% constant currency growth)
- Adjusted EBITDA of $632 million to $641 million (5.5% to 7% constant currency growth)
- Adjusted EPS of $0.93 to $1.01; capex $175 million to $225 million
Management cited a strong start to Q2, robust customer engagement, and continued operational discipline as key drivers, while noting that foreign exchange benefits will be front-loaded in the first half and that segment mix will remain a key determinant of margin trajectory.
- Segment mix and regulatory execution remain central to near-term results
- Customer onboarding and x-ray facility ramp expected to contribute in the second half
Takeaways
Sotera Health’s Q1 2026 results reinforce its position as a resilient, contract-driven healthcare services provider with levers for margin expansion and risk mitigation.
- Segment Mix Is Driving Margin Upside: Nordion’s outperformance and Sterigenics’ pricing discipline are offsetting Nelson Labs’ drag, supporting consolidated margin gains.
- Regulatory and Legal Dynamics Remain Pivotal: Compliance investments and legal wins reduce risk, but regulatory clarity will dictate medium-term capital allocation and competitive positioning.
- Watch for Nelson Labs Execution and Leadership Transition: Sustained margin recovery and growth in Nelson Labs, along with smooth CEO handoff, will be critical for maintaining momentum into the back half of 2026.
Conclusion
Sotera Health delivered a strategically favorable Q1, with segment outperformance and margin expansion offsetting continued softness in testing services. The company’s reaffirmed guidance, strong balance sheet, and operational discipline position it well for the remainder of the year, but regulatory and execution risks warrant close monitoring as leadership transitions and industry rules evolve.
Industry Read-Through
Sotera Health’s Q1 results offer several industry signals: Pricing power and regulatory compliance are increasingly critical in the healthcare sterilization and lab testing markets, favoring scale players with embedded customer relationships and the capital to invest in upgrades. The Cobalt-60 supply chain remains volatile, and timing-driven swings in segment results will likely persist for all gamma sterilization players. Regulatory scrutiny on ethylene oxide emissions is shaping capital allocation and may accelerate consolidation, as smaller operators struggle to keep pace with compliance costs. Lab testing demand is recovering but remains uneven, suggesting that end-market normalization is still in progress across the sector.